, Tracking Stock Market Picks
Enter Symbol:
Caladrius Biosciences Inc. (CLBS) [hlAlert]

down 95.73 %

NEOSTEM INC. (NBS) rated Buy with price target $15 by Maxim Group

Posted on: Friday,  Nov 14, 2014  9:25 AM ET by Maxim Group

Maxim Group rated Buy Caladrius Biosciences Inc. (NASDAQ: CLBS) on 11/14/2014. Previously Maxim Group rated Buy Caladrius Biosciences Inc. (NASDAQ: CLBS) on
05/27/2010., when the stock price was $30.00. Since then, Caladrius Biosciences Inc. has lost 95.73% as of 01/08/2016's recent price of $1.28.
If you would have followed the previous Maxim Group's recommendation on CLBS, you would have lost 95.73% of your investment in 2052 days.

NeoStem, Inc. (NeoStem) is engaged in a platform business of operating a commercial autologous (donor and recipient are the same) adult stem cell bank and in pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the United States. It also entered the research and development arenas, through the acquisition of a worldwide license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSEL (very small embryonic-like) stem cells. VSELs have many physical characteristics typically found in embryonic stem cells, including the ability to differentiate into specialized cells found in substantially all the different types of cells and tissue that make up the body. In October 2009, NeoStem, Inc. completed the acquisition of China Biopharmaceuticals Holdings, Inc.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/14/2014 9:25 AM Buy
5.41 15.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/27/2010 8:25 AM Buy
30.00 50.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy